Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).

Jacobs SS, Stork LC, Bostrom BC, Hutchinson R, Holcenberg J, Reaman GH, Erdmann G, Franklin J, Neglia JP, Steinberg SM, Balis FM, Adamson PC; Children's Oncology Group; National Cancer Institute.

Pediatr Blood Cancer. 2007 Sep;49(3):250-5.

PMID:
16856155
2.

Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.

Lowe ES, Kitchen BJ, Erdmann G, Stork LC, Bostrom BC, Hutchinson R, Holcenberg J, Reaman GH, Woods W, Franklin J, Widemann BC, Balis FM, Murphy RF, Adamson PC.

Cancer Chemother Pharmacol. 2001 Mar;47(3):199-205.

3.

The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.

Lennard L, Richards S, Cartwright CS, Mitchell C, Lilleyman JS, Vora A; UK MRC/NCRI Childhood Leukaemia Working Party.

Clin Pharmacol Ther. 2006 Oct;80(4):375-83.

PMID:
17015055
4.

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.

Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H, Hutchinson R, Heerema NA, Sorrell AD, Masterson M, Bleyer A, Gaynon PS.

Blood. 2010 Apr 8;115(14):2740-8. doi: 10.1182/blood-2009-07-230656. Epub 2010 Feb 1.

5.

Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.

Stoneham S, Lennard L, Coen P, Lilleyman J, Saha V.

Br J Haematol. 2003 Oct;123(1):100-2.

PMID:
14510948
6.
7.

Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.

Harms DO, Göbel U, Spaar HJ, Graubner UB, Jorch N, Gutjahr P, Janka-Schaub GE; COALL Study Group.

Blood. 2003 Oct 15;102(8):2736-40. Epub 2003 Jul 3.

9.

A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.

Kitchen BJ, Balis FM, Poplack DG, O'Brien M, Craig CE, Adamson PC.

Clin Cancer Res. 1997 May;3(5):713-7.

10.
11.

Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.

Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, Bleyer WA.

Blood. 1998 Nov 15;92(10):3569-77.

13.

A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).

Bell BA, Brockway GN, Shuster JJ, Erdmann G, Sterikoff S, Bostrom B, Camitta BM; Pediatric Oncology Group study (now The Children's Oncology Group).

Pediatr Blood Cancer. 2004 Aug;43(2):105-9.

PMID:
15236274
14.

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.

Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, Erdmann GR, Gold S, Heerema NA, Hutchinson RJ, Provisor AJ, Trigg ME; Children's Cancer Group.

Blood. 2003 May 15;101(10):3809-17. Epub 2003 Jan 16.

15.

Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881.

Hutchinson RJ, Gaynon PS, Sather H, Bertolone SJ, Cooper HA, Tannous R, Wells LM, Heerema NA, Sailer S, Trigg ME; Children's Cancer Group/Children's Oncology Group.

J Clin Oncol. 2003 May 1;21(9):1790-7.

PMID:
12721256
16.

Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia.

Lancaster DL, Patel N, Lennard L, Lilleyman JS.

Cancer Chemother Pharmacol. 2002 Jul;50(1):33-6. Epub 2002 Apr 27.

PMID:
12111109
17.

Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia.

Jacqz-Aigrain E, Nafa S, Médard Y, Bessa E, Lescoeur B, Vilmer E.

Eur J Clin Pharmacol. 1997;53(1):71-4.

PMID:
9349933
18.

Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.

Escherich G, Göbel U, Jorch N, Spaar HJ, Janka-Schaub GE.

Klin Padiatr. 2007 May-Jun;219(3):134-8.

PMID:
17525906
19.

Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.

Barredo JC, Devidas M, Lauer SJ, Billett A, Marymont M, Pullen J, Camitta B, Winick N, Carroll W, Ritchey AK.

J Clin Oncol. 2006 Jul 1;24(19):3142-9.

PMID:
16809737
20.

Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.

Winter SS, Holdsworth MT, Devidas M, Raisch DW, Chauvenet A, Ravindranath Y, Ducore JM, Amylon MD.

Pediatr Blood Cancer. 2006 Feb;46(2):179-86.

PMID:
16007607

Supplemental Content

Support Center